NCT00063310View on ClinicalTrials.gov

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Alzheimer Disease
Interventions
DRUG

Leuprolide acetate

Trial Locations (3)

33321

Baumel-Eisner Neuromedical Institute, Fort Lauderdale

33710

Meridien Research, St. Petersburg

85351

Sun Health Research Institute, Sun City

All Listed Sponsors
lead

Voyager Pharmaceutical Corporation

INDUSTRY

NCT00063310 - ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation | Biotech Hunter | Biotech Hunter